[HTML][HTML] Identification of a transcriptomic prognostic signature by machine learning using a combination of small cohorts of prostate cancer
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
[引用][C] Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer
B Vittrant, M Leclercq, ML Martin-Magniette… - Frontiers in Genetics …, 2020 - jglobal.jst.go.jp
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a
Combination of Small Cohorts of Prostate Cancer | Article Information | J-GLOBAL Art J-GLOBAL …
Combination of Small Cohorts of Prostate Cancer | Article Information | J-GLOBAL Art J-GLOBAL …
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer
B Vittrant, M Leclercq, ML Martin-Magniette… - Frontiers in …, 2020 - hal.science
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer.
B Vittrant, M Leclercq, ML Martin-Magniette… - Frontiers in …, 2020 - europepmc.org
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
[HTML][HTML] Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer
B Vittrant, M Leclercq, ML Martin-Magniette… - Frontiers in …, 2020 - ncbi.nlm.nih.gov
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer
B Vittrant, M Leclercq… - Frontiers in …, 2020 - pubmed.ncbi.nlm.nih.gov
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer
B Vittrant, M Leclercq, ML Martin-Magniette, C Collins… - 2020 - agris.fao.org
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
Identification of a Transcriptomic Prognostic Signature by Machine Learning Using a Combination of Small Cohorts of Prostate Cancer.
B Vittrant, M Leclercq, ML Martin-Magniette… - Frontiers in …, 2020 - europepmc.org
Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …